Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.
Journal
Blood cancer discovery
ISSN: 2643-3249
Titre abrégé: Blood Cancer Discov
Pays: United States
ID NLM: 101764786
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
African Americans are at higher risk of multiple myeloma (MM) yet underrepresented in clinical trials and reap less benefits from novel therapies of the disease. To improve representation of African Americans in MM clinical trials, researchers, providers, patients, industry partners and regulators at the FDA-AACR workshop developed recommendations to all stakeholders. The outlined principles offer a roadmap to addressing disparities broadly in clinical trials.
Identifiants
pubmed: 34179821
doi: 10.1158/2643-3230.BCD-20-0123
pmc: PMC8224821
mid: NIHMS1714122
pii: 2643-3230.BCD-20-0123
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
119-124Subventions
Organisme : NCI NIH HHS
ID : P01 CA155258
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100707
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207237
Pays : United States
Références
Blood Cancer J. 2018 Oct 10;8(10):96
pubmed: 30305608
JNCI Cancer Spectr. 2020 Apr 24;4(4):pkaa034
pubmed: 32704619
CA Cancer J Clin. 2019 May;69(3):211-233
pubmed: 30762872
Blood Adv. 2019 Oct 22;3(20):2986-2994
pubmed: 31648322
Blood. 2010 Dec 16;116(25):5501-6
pubmed: 20823456
Leukemia. 2014 May;28(5):1122-8
pubmed: 24157580
JAMA Oncol. 2019 Oct 01;5(10):e191870
pubmed: 31415071
JCO Oncol Pract. 2020 Jul;16(7):422-430
pubmed: 32574128
J Diabetes Sci Technol. 2020 Mar;14(2):345-349
pubmed: 30862182